Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial
US-based biotechnology company Corcept Therapeutics has reported positive long-term outcomes from its Phase III study of relacorilant, a treatment for…
Metabolic Disorders
-
-
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns
BioAge Labs has halted the Phase II randomised STRIDES trial of its investigational drug azelaprag, both as single agent and…
-
Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy
Eli Lilly has scored a win in the ongoing competition with Novo Nordisk in the obesity space, as a Phase…
-
Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment
Arrowhead Pharmaceuticals has submitted an application to the New Zealand Medicines and Medical Devices Safety Authority seeking clearance to commence…
-
Sidra Medicine conducts paediatric congenital hyperinsulinism trial
Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital hyperinsulinism. The first pharmaceutical trial comes…
-
Lexicon completes subject enrolment for DPNP trial of LX9211
Lexicon Pharmaceuticals has completed the enrolment of subjects for the multicentre, Phase IIb PROGRESS trial of the new adaptor-associated kinase…
-
AHA 2024: GLP-1R agonist associated with better clinical outcomes in heart failure and CKD
On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the safety of glucagon-like peptide-1 receptor (GLP-1R)…
-
AHA 2024: semaglutide continues to impress in diabetic kidney disease
At this year’s American Heart Association (AHA) conference, during a main event session on the topic of 'GLP-1RAs and Beyond:…
-
Amgen speaks out about bone density concerns with obesity drug
Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s…
-
Viking stock fluctuates amid manufacturing concerns with obesity pill
Shares in Viking Therapeutics jumped after the company shared positive data from an early-stage trial of its obesity pill but…
